You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDexmethylphenidate
Accession NumberDB06701
TypeSmall Molecule
GroupsApproved
Description

Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Structure
Thumb
Synonyms
d-threo-methylphenidate
D-TMP
Dexmethylphenidate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexmethylphenidate Hydrochloridetablet2.5 mg/1oralSandoz Inc2015-04-27Not applicableUs
Dexmethylphenidate Hydrochloridetablet10 mg/1oralSandoz Inc2015-04-27Not applicableUs
Dexmethylphenidate Hydrochloridetablet5 mg/1oralSandoz Inc2015-04-27Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release40 mg/1oralSandoz Inc2014-03-04Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release15 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release30 mg/1oralSandoz Inc2014-01-02Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release20 mg/1oralSandoz Inc2015-06-22Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release15 mg/1oralSandoz Inc2014-01-28Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release10 mg/1oralSandoz Inc2015-02-03Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release5 mg/1oralSandoz Inc2014-11-12Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release20 mg/1oralAvera Mc Kennan Hospital2015-12-01Not applicableUs
Focalintablet2.5 mg/1oralNovartis Pharmaceuticals Corporation2001-11-30Not applicableUs
Focalintablet10 mg/1oralNovartis Pharmaceuticals Corporation2001-11-30Not applicableUs
Focalintablet5 mg/1oralNovartis Pharmaceuticals Corporation2001-11-30Not applicableUs
Focalin XRcapsule, extended release15 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release40 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release30 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release20 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release10 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release15 mg/1oralSTAT Rx USA LLC2005-05-31Not applicableUs
Focalin XRcapsule, extended release5 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release35 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalin XRcapsule, extended release25 mg/1oralNovartis Pharmaceuticals Corporation2005-05-31Not applicableUs
Focalinxrcapsule, extended release20 mg/1oralPhysicians Total Care, Inc.2006-10-11Not applicableUs
Focalinxrcapsule, extended release15 mg/1oralPhysicians Total Care, Inc.2006-10-11Not applicableUs
Focalinxrcapsule, extended release10 mg/1oralPhysicians Total Care, Inc.2006-10-11Not applicableUs
Focalinxrcapsule, extended release5 mg/1oralPhysicians Total Care, Inc.2006-10-11Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dexmethylphenidate Hydrochloridetablet5 mg/1oralKvk Tech, Inc2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release40 mg/1oralTeva Pharmaceuticals USA Inc2013-11-21Not applicableUs
Dexmethylphenidate Hydrochloridetablet2.5 mg/1oralTeva Pharmaceuticals USA Inc2007-06-08Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release30 mg/1oralActavis Pharma, Inc.2014-02-24Not applicableUs
Dexmethylphenidate Hydrochloridetablet10 mg/1oralKvk Tech, Inc2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release30 mg/1oralTeva Pharmaceuticals USA Inc2014-05-22Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release20 mg/1oralActavis Pharma, Inc.2015-12-21Not applicableUs
Dexmethylphenidate Hydrochloridetablet2.5 mg/1oralKvk Tech, Inc2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridetablet5 mg/1oralAvera Mc Kennan Hospital2015-04-29Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release15 mg/1oralActavis Pharma, Inc.2014-11-11Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release40 mg/1oralMylan Pharmaceuticals Inc.2015-08-26Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release20 mg/1oralTeva Pharmaceuticals USA Inc2015-06-22Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release5 mg/1oralAvera Mc Kennan Hospital2015-03-06Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release10 mg/1oralActavis Pharma, Inc.2015-08-06Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release30 mg/1oralMylan Pharmaceuticals Inc.2013-11-18Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release15 mg/1oralTeva Pharmaceuticals USA Inc2014-05-21Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release5 mg/1oralActavis Pharma, Inc.2015-08-06Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release20 mg/1oralMylan Pharmaceuticals Inc.2015-12-21Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release10 mg/1oralTeva Pharmaceuticals USA Inc2015-02-02Not applicableUs
Dexmethylphenidate Hydrochloridetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2013-09-26Not applicableUs
Dexmethylphenidate Hydrochloridetablet2.5 mg/1oralGAVIS Pharmaceuticals, LLC2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release15 mg/1oralMylan Pharmaceuticals Inc.2015-08-26Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release5 mg/1oralTeva Pharmaceuticals USA Inc2014-11-10Not applicableUs
Dexmethylphenidate Hydrochloridetablet5 mg/1oralSun Pharmaceutical Industries, Inc.2013-09-26Not applicableUs
Dexmethylphenidate Hydrochloridetablet10 mg/1oralGAVIS Pharmaceuticals, LLC2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release10 mg/1oralMylan Pharmaceuticals Inc.2015-08-26Not applicableUs
Dexmethylphenidate Hydrochloridetablet10 mg/1oralTeva Pharmaceuticals USA Inc2007-06-08Not applicableUs
Dexmethylphenidate Hydrochloridetablet5 mg/1oralGAVIS Pharmaceuticals, LLC2015-12-04Not applicableUs
Dexmethylphenidate Hydrochloridecapsule, extended release5 mg/1oralMylan Pharmaceuticals Inc.2015-08-26Not applicableUs
Dexmethylphenidate Hydrochloridetablet5 mg/1oralTeva Pharmaceuticals USA Inc2007-06-08Not applicableUs
Dexmethylphenidate Hydrochloridetablet2.5 mg/1oralSun Pharmaceutical Industries, Inc.2013-09-26Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release30 mg/1oralPar Pharmaceuticals, Inc.2013-11-19Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release15 mg/1oralPar Pharmaceuticals, Inc.2013-11-19Not applicableUs
Dexmethylphenidate Hydrochloride Extended-releasecapsule, extended release30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AttenadeCelgene
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dexmethylphenidate hydrochloride
ThumbNot applicableDBSALT001458
Categories
UNIIM32RH9MFGP
CAS number40431-64-9
WeightAverage: 233.3062
Monoisotopic: 233.141578857
Chemical FormulaC14H19NO2
InChI KeyDUGOZIWVEXMGBE-CHWSQXEVSA-N
InChI
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1
IUPAC Name
methyl (2R)-2-phenyl-2-[(2R)-piperidin-2-yl]acetate
SMILES
COC(=O)[C@@H]([[email protected]]1CCCCN1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Aralkylamine
  • Piperidine
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationDexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.
PharmacodynamicsMethylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy.
Mechanism of actionMethylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.
Related Articles
Absorption11-52%
Volume of distributionNot Available
Protein binding30%
Metabolism

epatic, methylphenidate is metabolized primarily by de-esterification to ritalinic acid (α-phenyl-2-piperidine acetic acid, PPAA), which has little to no pharmacologic activity.

SubstrateEnzymesProduct
Dexmethylphenidate
Not Available
Ritalinic acidDetails
Route of eliminationRenal
Half life2-4 hours
ClearanceNot Available
ToxicityInsomnia, dizziness, nausea, stomach pain, euphoria, headache, anxiety, anorexia, and weight loss are common side effects. Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9663
Caco-2 permeable+0.6564
P-glycoprotein substrateSubstrate0.5466
P-glycoprotein inhibitor INon-inhibitor0.7964
P-glycoprotein inhibitor IINon-inhibitor0.9601
Renal organic cation transporterInhibitor0.532
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5985
CYP450 1A2 substrateNon-inhibitor0.592
CYP450 2C9 inhibitorNon-inhibitor0.897
CYP450 2D6 inhibitorNon-inhibitor0.5245
CYP450 2C19 inhibitorNon-inhibitor0.9265
CYP450 3A4 inhibitorNon-inhibitor0.8539
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9328
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9648
BiodegradationNot ready biodegradable0.5759
Rat acute toxicity2.7718 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8466
hERG inhibition (predictor II)Non-inhibitor0.7491
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral2.5 mg/1
Tabletoral5 mg/1
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral15 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral25 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral35 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral5 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5837284 No1995-12-042015-12-04Us
US5908850 No1995-12-042015-12-04Us
US6228398 No1999-11-012019-11-01Us
US6355656 No1995-12-042015-12-04Us
US6528530 No1995-12-042015-12-04Us
US6635284 No1995-12-042015-12-04Us
US6730325 No1999-11-012019-11-01Us
US7431944 No1995-12-042015-12-04Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP1.47ALOGPS
logP2.25ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity66.73 m3·mol-1ChemAxon
Polarizability26.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Arie Gutman, “Process for the preparation of dexmethylphenidate hydrochloride.” U.S. Patent US20040180928, issued September 16, 2004.

US20040180928
General ReferencesNot Available
External Links
ATC CodesN06BA11
AHFS Codes
  • 28:20.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dexmethylphenidate.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Dexmethylphenidate.
Aluminum hydroxideAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
AmitriptylineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amoxapine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dexmethylphenidate.
AtomoxetineAtomoxetine may increase the hypertensive activities of Dexmethylphenidate.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Dexmethylphenidate.
Calcium carbonateCalcium carbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Dexmethylphenidate.
CimetidineCimetidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Dexmethylphenidate.
ClomipramineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Clomipramine.
DesipramineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Desipramine.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Dexmethylphenidate.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Dexmethylphenidate.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Dexmethylphenidate.
DoxepinThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxepin.
DoxofyllineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxofylline.
DronabinolDronabinol may increase the tachycardic activities of Dexmethylphenidate.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Dexmethylphenidate.
EsomeprazoleEsomeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
FamotidineFamotidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Dexmethylphenidate.
FormoterolThe risk or severity of adverse effects can be increased when Formoterol is combined with Dexmethylphenidate.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Dexmethylphenidate.
ImipramineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Imipramine.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dexmethylphenidate.
Ioflupane I 123Dexmethylphenidate may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Dexmethylphenidate.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Dexmethylphenidate.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dexmethylphenidate.
LansoprazoleLansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
LinezolidLinezolid may increase the hypertensive activities of Dexmethylphenidate.
Magnesium hydroxideMagnesium hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Magnesium oxideMagnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Dexmethylphenidate.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Dexmethylphenidate.
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Dexmethylphenidate.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Dexmethylphenidate.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Dexmethylphenidate.
MoclobemideMoclobemide may increase the hypertensive activities of Dexmethylphenidate.
NaphazolineThe risk or severity of adverse effects can be increased when Naphazoline is combined with Dexmethylphenidate.
NizatidineNizatidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Dexmethylphenidate.
NortriptylineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Nortriptyline.
OmeprazoleOmeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Dexmethylphenidate.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dexmethylphenidate.
PantoprazolePantoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
PhenelzinePhenelzine may increase the hypertensive activities of Dexmethylphenidate.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Dexmethylphenidate.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Dexmethylphenidate.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dexmethylphenidate.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Dexmethylphenidate.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Dexmethylphenidate.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Dexmethylphenidate.
PrimidoneThe serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Dexmethylphenidate.
ProcarbazineProcarbazine may increase the hypertensive activities of Dexmethylphenidate.
ProtriptylineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline.
RabeprazoleRabeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RanitidineRanitidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
RasagilineRasagiline may increase the hypertensive activities of Dexmethylphenidate.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Dexmethylphenidate.
SalmeterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Dexmethylphenidate.
SelegilineSelegiline may increase the hypertensive activities of Dexmethylphenidate.
Sodium bicarbonateSodium bicarbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Dexmethylphenidate.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Dexmethylphenidate.
TranylcypromineTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.
TrimipramineThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Dexmethylphenidate.
Food Interactions
  • Avoid alcohol
  • Avoid excessive quantities of coffee or tea (caffeine)
  • Take on empty stomach: 1 hour before or 2 hours after meals

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61. doi: 10.1097/JCP.0b013e3181733560. [PubMed:18480678 ]
  2. Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997 May;131(1):71-8. [PubMed:9181638 ]
  3. Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb;160(1):92-8. Epub 2001 Dec 18. [PubMed:11862378 ]
  4. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang GJ, Logan J, Ding YS, Franceschi D, Gifford A, Morgan A, Pappas N, King P: Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse. 1999 Jan;31(1):59-66. [PubMed:10025684 ]
  5. Wayment HK, Deutsch H, Schweri MM, Schenk JO: Effects of methylphenidate analogues on phenethylamine substrates for the striatal dopamine transporter: potential as amphetamine antagonists? J Neurochem. 1999 Mar;72(3):1266-74. [PubMed:10037500 ]
  6. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  7. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Ding YS, Hitzemann R, Pappas N: Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 1999;65(1):PL7-12. [PubMed:10403500 ]
  8. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  10. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  11. Viggiano D, Vallone D, Sadile A: Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling. Neural Plast. 2004;11(1-2):97-114. [PubMed:15303308 ]
  12. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Markowitz JS, Patrick KS: Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61. doi: 10.1097/JCP.0b013e3181733560. [PubMed:18480678 ]
  2. Ding YS, Fowler JS, Volkow ND, Dewey SL, Wang GJ, Logan J, Gatley SJ, Pappas N: Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl). 1997 May;131(1):71-8. [PubMed:9181638 ]
  3. Davids E, Zhang K, Tarazi FI, Baldessarini RJ: Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl). 2002 Feb;160(1):92-8. Epub 2001 Dec 18. [PubMed:11862378 ]
  4. Yang L, Wang YF, Li J, Faraone SV: Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry. 2004 Sep;43(9):1154-8. [PubMed:15322419 ]
  5. Williard RL, Middaugh LD, Zhu HJ, Patrick KS: Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb;18(1):39-51. [PubMed:17218796 ]
  6. Chuhan YS, Taukulis HK: Impairment of single-trial memory formation by oral methylphenidate in the rat. Neurobiol Learn Mem. 2006 Mar;85(2):125-31. Epub 2005 Oct 24. [PubMed:16246598 ]
  7. Gray JD, Punsoni M, Tabori NE, Melton JT, Fanslow V, Ward MJ, Zupan B, Menzer D, Rice J, Drake CT, Romeo RD, Brake WG, Torres-Reveron A, Milner TA: Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 2007 Jul 4;27(27):7196-207. [PubMed:17611273 ]
  8. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci. 2001 Feb 15;21(4):1413-9. [PubMed:11160413 ]
  9. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  10. Tilley MR, Gu HH: The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther. 2008 Nov;327(2):554-60. doi: 10.1124/jpet.108.141713. Epub 2008 Aug 12. [PubMed:18698001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, Karp J, Kung HF: In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999 Apr;26(4):342-7. [PubMed:10199939 ]
  2. Izenwasser S, Coy AE, Ladenheim B, Loeloff RJ, Cadet JL, French D: Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol. 1999 Jun 4;373(2-3):187-93. [PubMed:10414438 ]
  3. Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Owens MJ, Votaw JR, Goodman MM: Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography. J Med Chem. 2006 Nov 16;49(23):6760-7. [PubMed:17154506 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on May 06, 2010 10:32 / Updated on May 25, 2016 02:16